GlycoMimetics Presents at ASH Meeting First-in-Human Data Showing Favorable Safety, Metabolic and Biomarker Profiles for GMI-1271
Initial top-line readout from on-going AML trial with GMI-1271 anticipated for mid 2016
"We are encouraged to see this biomarker evidence, demonstrating the
ability of GMI-1271 to target and reduce E-selectin as predicted," said
The data presented at ASH, prepared by researchers at
GMI-1271
targets E-selectin, a cell adhesion molecule that aids in blood cancer
cell resistance to chemotherapy. Preclinical studies have shown on a
cellular level how GMI-1271 can overcome E-selectin-induced resistance
to chemotherapy in AML and other blood cancers. The drug candidate is in
a Phase 1/2 clinical study designed to evaluate its safety,
pharmacokinetics (PK) and efficacy when used together with chemotherapy
for AML. Preclinical studies have also shown beneficial effect on
thrombosis without increasing bleeding time.
The abstract (Abstract #1004), entitled "First in Human Phase 1 Single Dose Escalation Studies of the E-Selectin Antagonist GMI-1271 Show a Favorable Safety, Pharmacokinetic, and Biomarker Profile," is available at ASH's website.
About
GlycoMimetics's wholly-owned drug candidate (GMI-1271) for AML and other
blood disorders is also in clinical trials.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements regarding the
clinical development of the GMI-1271 and the presentation of data.
Actual results may differ materially from those in these forward-looking
statements. For a further description of the risks associated with these
statements, as well as other risks facing
View source version on businesswire.com: http://www.businesswire.com/news/home/20151205005037/en/
Investor:
sannes@annesassociates.com
or
Media:
jamielacey@presscommpr.com
Source:
News Provided by Acquire Media